A short, lab-made peptide studied for brain signaling in cells and mice. No human clinical trials have been identified. It is coming soon to Promise, with a licensed provider reviewing requests when visits open.
Coming soon
You are on the list. We will email you when PE-22-28 becomes available — and nothing else. Joining is not a medical request, and no prescription has been issued.
That did not go through. Check the address and try again.
PE-22-28 is coming soon to Promise. Add your email and we'll let you know when visits open.
A licensed provider reviews every request; not everyone qualifies.
Every treatment gets its own online clinical questionnaire — your history, medications, and goals.
A real person goes through your history and takes the time to get it right before anything is decided.
If a treatment isn't right for your history, you'll hear that plainly. That review is the whole point.
Made for your prescription by a licensed U.S. pharmacy and shipped in temperature-safe packaging.
Your care team checks in after it arrives. Adjust with your provider, or cancel at any time.
PE-22-28 is easy to find online and hard to trust there. Promise works the way medicine is supposed to work — a clinician decides, a licensed pharmacy fills, and someone stays accountable to you.
Prescribed for you specifically, after a real look at your health history — never pulled off a shelf.
Your prescription is compounded for you by a licensed U.S. pharmacy — not a mystery vial from an unregulated website.
Temperature-safe shipping, follow-up check-ins, and a care team that answers — before and after your medication arrives.
Researchers have examined this short spadin analog at TREK-1, a cell channel involved in electrical signaling. That research does not establish a mood benefit in people.
The published research includes cell experiments and mouse studies. Human clinical trials have not been identified, leaving effects on symptoms and human safety unanswered.
When visits open, a licensed provider will review your health history and the early research, then decide whether a prescription is appropriate or decline.
PE-22-28 is a short, lab-made peptide studied for mood-related brain signaling. The evidence is from cell experiments and mice; no human clinical trials have been identified. It isn't a substitute for care of a diagnosed mood condition.
PE-22-28 is coming soon to Promise — add me to the list.
A peptide is a short chain of amino acids, the building blocks of proteins. This one has seven. It is a shortened spadin analog, meaning a molecule built from the structure of another molecule.
The starting point was sortilin, a protein that cells make in a larger, unfinished form. As that form matures, it releases a small piece called a propeptide. Researchers used part of that piece to design spadin, as described in the 2010 spadin study. The shorter chain came later.
That origin explains the family name. It does not mean that the synthetic peptide has been tested in people simply because its starting sequence comes from a protein found in the body. A molecule's origin and its clinical evidence are separate questions.
The target is TREK-1, a potassium channel: a small passage in a cell's outer membrane that helps control electrical activity. In nerve cells, that activity is part of how signals are sent. Researchers have examined the short peptide as a blocker of this channel in laboratory experiments.
Blocking a channel gives researchers a specific question to test. They can measure an electrical change in a cell, then ask whether that change is linked to behavior in an animal. Neither measurement tells them how a person will feel.
This is why a mechanism alone cannot settle a question about mood. It describes the proposed starting point. Human studies would need to examine symptoms, unwanted effects and how the compound behaves in the body.
The 2017 study of shortened spadin analogs examined TREK-1 activity in cells and behavior in mice. It also examined markers of new cells in the hippocampus, a brain region involved in memory and mood. The mouse groups in its new-cell experiment were small, with five animals per group.
The paper discusses neurogenesis, which means the formation of new nerve cells. The researchers measured cell-labeling markers; they did not measure recovery from depression in people. That distinction also applies to interest in a faster response: timing in a mouse experiment cannot establish when a person's symptoms would change.
Human clinical trials have not been identified in the published literature or trial registry searched for this page. That leaves basic questions unanswered, including safety, interactions with other medicines and any effect on symptoms. A short animal experiment cannot establish the safety of longer use in people.
Prescription antidepressants include medicines with controlled clinical studies in people. For example, fluoxetine has human trial data and acts on serotonin uptake, the process by which nerve cells take back a chemical messenger. The experimental peptide's research centers on a potassium channel instead.
Those different starting points do not show that one is faster, gentler or a replacement for the other. There is no human comparison trial here to support that choice.
This peptide is not a substitute for care of diagnosed depression or anxiety. Prescribed medicines are not changed without the prescriber. Interest in a new molecule can be part of a conversation about care, without changing an existing plan on the strength of mouse findings.
These names sometimes appear together, but they describe different molecules. Selank has been examined in nasal studies in rats around GABA, a chemical messenger that helps quiet nerve-cell signaling. Semax has been studied in rats around proteins involved in nerve-cell signaling and maintenance.
Neither sibling's research can fill the gaps in this peptide's evidence. A shared interest in brain signaling does not make their mechanisms, clinical records or safety interchangeable. The Mood & Libido hub provides the wider category context; placement there describes the research topic, not a finding of benefit for a mood condition.
When visits open, the process will begin with an intake questionnaire written for this compound. It will cover health history, current medicines and supplements, mental-health history and the reason for the request.
A licensed provider will review your answers and may ask for more information, prescribe when appropriate or decline. Your provider sets any protocol; Promise does not publish dosing. If prescribed, a licensed U.S. pharmacy will compound and dispense the medication, with follow-up check-ins from your care team.
The formulation Promise will offer is a compounded medication, which is different from an FDA-approved product. That formulation is not FDA-approved. Compounded medications are not reviewed by the FDA for safety, effectiveness, or quality.
A licensed provider may still prescribe — that decision is between you and your doctor.
It is a lab-made peptide, a short chain of seven amino acids. It is a shortened version of spadin, a peptide designed from part of the protein sortilin. Researchers have examined it at TREK-1, a potassium channel involved in cell signaling. Its evidence is from cell experiments and mice, with no human clinical trials identified.
Yes. When visits open, PE-22-28 will be prescribed by a licensed provider after a review of your health history and compounded for you by a licensed U.S. pharmacy. It will not be a product labeled for laboratory use. A prescription will depend on the provider's decision about whether it is appropriate for you.
A visit does not guarantee a prescription. When visits open, a licensed provider will review the intake and decide whether prescribing is appropriate. They may ask for more information or decline. Joining the waitlist only requests an email when visits open; it does not begin a medical evaluation or secure a prescription.
No. PE-22-28 is not FDA-approved, and no FDA-approved product contains it. The formulation Promise will offer is a compounded medication, which is not reviewed by the FDA for safety, effectiveness, or quality. A prescription would reflect an individual provider's decision, not a finding of human benefit or safety.
Not yet. PE-22-28 is coming soon to Promise — add me to the list on this page and we'll email you when visits open. The page explains the early research and the future prescription process. Joining the list is a request for notification, and does not begin a visit or mean a prescription will be issued.
Its research starts with a different target: TREK-1, a potassium channel. Common prescription antidepressants include medicines studied in people that act on chemical messengers such as serotonin. This short peptide has no identified human clinical trials and is not a substitute for care of a diagnosed mood condition. Prescribed medicines are not changed without the prescriber.
The research examines channel activity in cells, behavior in mice and markers of new cells in a mouse brain region. Those are laboratory measurements, not evidence that a person will feel better. Human benefit, safety and interactions with medicines remain unanswered by clinical trials. A provider review does not turn animal findings into human evidence.
Products sold online without a prescription may be labeled for laboratory use and come without a provider reviewing your health history or a pharmacy dispensing a prescription for you. When visits open, the Promise process will involve a licensed provider, a prescription only when appropriate, a licensed U.S. pharmacy and care-team follow-up. Those steps do not establish human safety or benefit.
Other Mood & Libido options a provider may consider.
Mood & Libido
A melanocortin receptor agonist, also called bremelanotide, studied for central nervous system pathways involved in sexual desire rather than peripheral blood flow.
Requires an online medical evaluation. Prescribed only when a licensed provider determines it's appropriate.
Type a treatment, a goal, or a question.